XL t(8;14)

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl


XL t(8;14)

This product has been replaced by XL t(8;14) MYC/IGH DF. Order Number D-5110-100-OG

Clinical Details

Chromosomal translocations affecting the IGH locus are recurrent in many types of lymphomas. The malignant transformation works via the juxtaposition of oncogenes next to regulatory sequences of the immunoglobulin locus.

The t(8;14)(q24;q32) MYC/IGH is the hallmark translocation of human Burkitt lymphoma where it accounts for about 85% of cases. The same translocation can be present in almost 5% of ALL patients and in diffuse large B-cell lymphomas. Although this aberration is often described to indicate a good prognosis, it can be an indicator of bad prognosis if associated with other factors, such as second aberrations like t(14;18) or BCL6 rearrangements.

Clinical Applications

  • Non-Hodgkin Lymphomas (NHL)
  • Acute Lymphoblastic Leukemia (ALL)


XL t(8;14)

XL t(8;14) hybridized to a metaphase cell. Two fusion signals and separated orange and green signals are displayed indicating a translocation between IGH and MYC.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange signals (2O).

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.


  • Siebert et al (1998) Blood 91:984-990
  • Hummel et al (2006) N Engl J Med 354:2419-30
  • Boerma et al (2009) Leukemia 23:225-234


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.